Iqra Mumal, MSc,  —

Iqra holds a MSc in Cellular and Molecular Medicine from the University of Ottawa in Ottawa, Canada. She also holds a BSc in Life Sciences from Queen’s University in Kingston, Canada. Currently, she is completing a PhD in Laboratory Medicine and Pathobiology from the University of Toronto in Toronto, Canada. Her research has ranged from across various disease areas including Alzheimer’s disease, myelodysplastic syndrome, bleeding disorders and rare pediatric brain tumors.

Articles by Iqra Mumal

Study Links Esbriet, Ofev to Significant Gastrointestinal Side Effects

Patients who take either Esbriet (pirfenidone, sold by Genentech) or Ofev (nintedanib, by Boehringer Ingelheim) — two anti-fibrotic therapies approved to treat idiopathic pulmonary fibrosis — often experience significant gastrointestinal side effects, a Dutch study shows. The study, “Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in…

Antineutrophil Cytoplasmic Antibodies Do Not Correlate with Disease Severity or Survival in North American IPF Patients

The presence of auto-antibodies (self-directed antibodies) known as antineutrophil cytoplasmic antibodies do not correlate with disease severity or survival in North American patients with idiopathic pulmonary fibrosis (IPF), according to a new study. The study, “Prevalence and Clinical Significance of Antineutrophil Cytoplasmic Antibodies in North American Patients with…

Cedars-Sinai Given $12M to Study IPF, Chronic Lung Allograft Dysfunction

The National Institutes of Health (NIH) has granted $12 million to researchers at Cedars-Sinai Medical Center to continue studying two lung diseases — idiopathic pulmonary fibrosis and chronic lung allograft dysfunction. Idiopathic pulmonary fibrosis (IPF) is characterized by progressive scarring of lung tissue which leads to difficulty breathing. Chronic lung allograft dysfunction is a complication…

Galectin Therapeutics Issued Patent for PF Therapy Candidate GR-MD-02

Galectin Therapeutics was issued a patent for its lead investigative therapy GR-MD-02 for the treatment of pulmonary fibrosis by the U.S. Patent and Trademark Office (USPTO), the company announced. GR-MD-02 is a carbohydrate-based medicine that binds and stops the action of the galectin-3 protein, which is directly involved in multiple…